Seres Therapeutics to Host Third Quarter 2020 Financial Results & Operational Progress Conference Call & Webcast on November ...
November 02 2020 - 7:00AM
Business Wire
Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome
platform company developing a novel class of multifunctional
bacterial therapeutics designed to functionally interact with host
cells and tissues to treat disease, today announced that management
will host a conference call and live audio webcast on November 9,
2020 at 8:30 a.m. ET to discuss third quarter 2020 results and
provide a general business update.
To access the conference call, please dial 844-277-9450
(domestic) or 336-525-7139 (international) and reference the
conference ID number 1038426. To join the live webcast, please
visit the “Investors and Media” section of the Seres website at
www.serestherapeutics.com.
A webcast replay will be available on the Seres website
beginning approximately two hours after the event and will be
archived for approximately 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome
therapeutics platform company developing a novel class of
multifunctional bacterial consortia that are designed to
functionally interact with host cells and tissues to treat disease.
Seres’ SER-109 program achieved the first-ever positive pivotal
clinical results for a targeted microbiome drug candidate and has
obtained Breakthrough Therapy and Orphan Drug designations from the
FDA. The SER-109 program is being advanced for the treatment of
recurrent C. difficile infection and has potential to become a
first-in-class FDA-approved microbiome therapeutic. Seres’ SER-287
program has obtained Fast Track and Orphan Drug designations from
the FDA and is being evaluated in a Phase 2b study in patients with
active mild-to-moderate ulcerative colitis. Seres is developing
SER-401 in a Phase 1b study in patients with metastatic melanoma,
SER-301 for ulcerative colitis and SER-155 to prevent mortality due
to gastrointestinal infections, bacteremia and graft versus host
disease. For more information, please visit
www.serestherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201102005075/en/
PR Contact Lisa Raffensperger
lisa@tenbridgecommunications.com
IR Contact Carlo Tanzi, Ph.D.
ctanzi@serestherapeutics.com
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Apr 2023 to Apr 2024